[Secondary hyperparathyroidism].
Imanishi
Yasuo
Y
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine.
Inaba
Masaaki
M
D000327:Adsorption; D001808:Blood Vessels / Q000473:pathology; D002114:Calcinosis / Q000209:etiology; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology; D000069449:Cinacalcet; D003937:Diagnosis, Differential; D000431:Ethanol / Q000008:administration & dosage; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D015552:Injections, Intralesional; D007676:Kidney Failure, Chronic / Q000150:complications; D009281:Naphthalenes / Q000627:therapeutic use; D010000:Osteitis / Q000209:etiology; D016105:Parathyroidectomy; D010758:Phosphorus / Q000302:isolation & purification; D011379:Prognosis; D006435:Renal Dialysis / Q000009:adverse effects; D014807:Vitamin D / Q000627:therapeutic use
D009281:Naphthalenes; D014807:Vitamin D; D010758:Phosphorus; D000431:Ethanol; D000069449:Cinacalcet